Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 114-120 , September 2010

Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?

  • Hui Cheng
    • ,
  • Thomas Force

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Thomas Force, Center for Translational Medicine, Thomas Jefferson University, College Building, Suite 316, 1025 Walnut St., Philadelphia, PA 19107.

References 

  1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187
  2. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298:1912–1934
  3. Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007;446:145–146
  4. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–837
  5. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035–1044
  6. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007;6:834–848
  7. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106:21–34
  8. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest. 2007;117:2067–2074
  9. Okram B, Nagle A, Adrian FJ, et al. A general strategy for creating “inactive-conformation” abl inhibitors. Chem Biol. 2006;13:779–786
  10. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004;11:1192–1197
  11. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–916
  12. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–2019
  13. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212
  14. Hoshijima M, Chien KR. Mixed signals in heart failure: cancer rules. J Clin Invest. 2002;109:849–855
  15. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465
  16. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol. 2009;10:356–360
  17. Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2:15–25
  18. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307–318
  19. Izumiya Y, Shiojima I, Sato K, et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47:887–893
  20. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446:444–448
  21. Khakoo AY. Regulation of hypertrophic responses by PDGFRβ. In: American Heart Association, Basic Cardiovascular Sciences annual meeting, Lake Las Vegas, NV; 2009 July 21st. 2009;
  22. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27:5511–5526
  23. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–5510
  24. Muslin AJ, DeBosch B. Role of Akt in cardiac growth and metabolism. Novartis Found Symp. 2006;274:118–126discussion 26-31, 52-55, 272-276
  25. McMullen JR, Jay PY. PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart. Cell Cycle. 2007;6:910–913
  26. Potts MB, Vaugha AE, McDonough H, et al. Reduced Apaf-1 levels in cardiomyocytes engage a strict regulation of apoptosis by endogenous XIAP. J Cell Biol. 2005;171:925–930
  27. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500–2508
  28. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118:84–95
  29. Fernandez A, Sanguino A, Peng Z, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007;117:4044–4054
  30. Demetri GD. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest. 2007;117:3650–3653
  31. Crespo A, Zhang X, Fernandez A. Redesigning kinase inhibitors to enhance specificity. J Med Chem. 2008;51:4890–4898
  32. Fernandez A, Crespo A, Tiwari A. Is there a case for selectively promiscuous anticancer drugs?. Drug Discov Today. 2009;14:1–5
  33. Alexis F, Pridgen EM, Langer R, et al. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010;55–86
  34. Basu S, Harfouche R, Soni S, et al. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A. 2009;106:7957–7961
  35. Harfouche R, Basu S, Soni S, et al. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis. 2009;12:325–338

 Statement of Conflict of Interest: see page 119.

PII: S0033-0620(10)00116-7

doi: 10.1016/j.pcad.2010.06.006

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 114-120 , September 2010

Article Tools

* Image Usage & Resolution